close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Insight Molecular Diagnostics Inc. - Common Stock (NQ:IMDX)

4.415 +0.135 (+3.16%)
Streaming Delayed Price Updated: 11:08 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Insight Molecular Diagnostics Inc. - Common Stock

News headline image
Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript ↗
FDA review nears completion as reimbursement rates support commercial launch. 
Via The Motley Fool
Topics Earnings
News headline image
Oncocyte Eyes Faster, Less Invasive Heart Transplant Rejection Testing ↗
Insight Molecular Diagnostics discussed the potential use of donor-derived cell-free DNA testing in heart transplant surveillance during a virtual session featuring transplant cardiologist Dr. Max... 
Via MarketBeat
News headline image
Oncocyte Q2 Earnings Call Highlights ↗
Oncocyte (NASDAQ:IMDX) executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial... 
Via MarketBeat
Topics Earnings
Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission ↗
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Exploring Insight Molecular's Earnings Expectations ↗
 
Via Benzinga
News headline image
IMDX Q1 2026 Earnings Call Transcript ↗
IMDX Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
These stocks are moving in today's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Topics Artificial Intelligence
News headline image
INSIGHT MOLECULAR DIAGNOSTIC (NASDAQ:IMDX) Stock Plummets 11.8% on Q3 Earnings Miss ↗
Insight Molecular Dx (IMDX) stock fell 11.8% after missing Q3 2025 revenue and EPS estimates. The company remains focused on its FDA submission for the GraftAssureDx™ test. 
Via Chartmill
News headline image
A Look at Insight Molecular's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.